Hoth Therapeutics

Real-time Quotes | Nasdaq Last Sale

Opening 11:17 12/02 EST
Corp Actions
Voltron Therapeutics, Inc. to Participate in the 2020 Fall Defense TechConnect Virtual Innovation Summit
Company Selected as a 2020 TechConnect Defense Innovation AwardeeNEW YORK, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Voltron Therapeutics, Inc. today announced that it will participate in the 2020 Fall TechConnect Virtual Innovation Conferences' Virtual Defense TechConnect Innovation Summit. The conference will be held November 17-19, 2020. Importantly, the Company was also selected as a 2020 TechConnect Defense Innovation Awardee.  The annual TechConnect Defense Innovation Awards recognizes the top 15% of submitted Challenge technologies as ranked by the Selection Committee.Voltron’s COVID-19 vaccine, HaloVax, is being developed using the novel Self Assembling Vaccine technology exclusively licensed from the Massachusetts General Hospital’s Vaccine and Immunotherapy Center, provides a novel approach to attacking the virus, and an important alternative to first generation vaccines in development.Entering its seventh year, the annual Defense TechConnect (DTC) Summit, co-located with the Fall SBIR/STTR Innovation Summit, brings together defense, private industry, federal agency, and academic leadership to accelerate state-of-the-art technology solutions for the warfighter and national security.The DTC supports innovation imperatives in the new National Defense Strategy (NDS) and is a unique platform to reach thousands of public and private leaders focused on innovation and technology to support the warfighter. At last year's Defense Innovation Summit, close to 1,000+ one-on-one meetings took place between small businesses and SBIR Federal Program Managers, 200+ booths and tabletop displays in the Exhibit Hall representing private sector companies and non-traditional innovators, and more than 30 breakout sessions focused on defense innovation areas of interest including but not limited to energy, cyber, biomedical, and command, control, communications, computers/intelligence, surveillance, and reconnaissance (C4ISR).The DTC Summit is proud to once again host the Defense Innovation Technology Acceleration Challenges (DITAC), connecting emerging technologies with DOD component commands, officers, and acquisition experts. The annual DTC is one of the most well-attended defense innovation conferences of the year.To learn more about the Virtual Defense TechConnect Summit and Expo, one of the most well-attended defense events of the year, please visit: Voltron Therapeutics, Inc.Voltron Therapeutics, Inc., a Delaware corporation, was founded in 2017 to lead and accelerate the development of the Vaccine and Immunotherapy Center (VIC), and the Massachusetts General Hospital’s novel Self Assembling Vaccine technology in a variety of indications, including in Oncology and emerging Infectious Diseases. Voltron holds an exclusive worldwide license to this technology. With the work of our world class team of researchers and physicians, this technology has shown in certain pre-clinical studies initial proof of concept in two infectious diseases (Lassa Fever and Q Fever) as well as two oncology indications (Ovarian and HPV Related Cancers). For more information, please visit HaloVax™, LLCHaloVax, LLC is a special purpose subsidiary of Voltron Therapeutics, Inc. in joint venture with Hoth Therapeutics, Inc. (NASDAQ: HOTH) The mission of HaloVax is to develop a novel, Self-Assembling Vaccine against COVID-19, utilizing technology licensed by Voltron Therapeutics, Inc. from the Vaccine and Immunotherapy Center at the Massachusetts General Hospital. The vaccine is being designed from a validated platform to provide customized T cell immunity against COVID-19, as well as be able to adapt rapidly to potential genetic drift of the virus. For more information, please visit About Hoth Therapeutics, Inc.Hoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth’s pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. To learn more, please visit Looking StatementsThis press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the advancement and development of the VaxCelerate Platform, the commencement of clinical trials, the availability of data from clinical trials and other information that is not historical information. When used herein, words such as “anticipate”, “being”, “will”, “plan”, “may”, “continue”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Voltron’s current expectations and various assumptions. Voltron believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Voltron may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, market conditions and any Voltron filings made with the Securities and Exchange Commission. Consequently, forward-looking statements should be regarded solely as Voltron’s current plans, estimates and beliefs. Investors should not place undue reliance on forward-looking statements. Voltron cannot guarantee future results, events, levels of activity, performance or achievements. Voltron does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.Investor Contacts:Matt Duffy President Voltron Therapeutics, Inc. 646-335-5923 mduffy@luciuspartnersllc.comJason Assad Investor Relations Voltron Therapeutics, Inc. 678-570-6791
GlobeNewswire · 11/16 16:30
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
Hoth Therapeutics nabs U.S. patent for targeted 13-Cis-RAMBA retinamides
U.S. Patent and Trademark Office has granted Hoth Therapeutics ([[HOTH]] +3.3%) patent No. 10,793,525 related to 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers. The patent
Seekingalpha · 10/20 16:48
Hoth Therapeutics Announces USPTO Grant of Patent for Targeted 13-Cis-RAMBA Retinamides for Development as a Novel Cancer Therapeutic
Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 10,793,525 related to novel 13-Cis-RAMBA retinamides optimized to target key signaling pathways implicated in a variety of cancers. This patent is also the first of its kind, expiring on October 5, 2036.
PR Newswire · 10/20 15:30
Hoth Therapeutics Reports US Patent And Trademark Office Grant For Patent On Targeted 13-Cis-RAMBA Retinamides For Development As Novel Cancer Therapeutics
Hoth Therapeutics, Inc. (NASDAQ:HOTH), a biopharmaceutical company, today announced that through its commercial licensing agreement with the University of Maryland, Baltimore (UMB) the U.S. Patent and Trademark
Benzinga · 10/20 14:31
The Daily Biotech Pulse: Aptinyx Jumps On Positive Readout, Cara Executes Korsuva Licensing Deal, Cleveland BioLabs Rallies On Reverse Merger
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 19)
Benzinga · 10/20 12:17
The Daily Biotech Pulse: FDA Nod For Pfizer, Sorrento's COVID-19 Antibody Animal Data, Orphazyme's Wall Street Debut
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 28)
Benzinga · 09/29 11:47
The Daily Biotech Pulse: Novavax Advances Vaccine, Marinus Gets Nod For Late-Stage Study, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 24)
Benzinga · 09/25 11:37
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HOTH. Analyze the recent business situations of Hoth Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts


Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HOTH stock price target is 9.00 with a high estimate of 10.00 and a low estimate of 7.00.
Institutional Holdings
Institutions: 32
Institutional Holdings: 210.38K
% Owned: 1.57%
Shares Outstanding: 13.44M
Sold Out
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About HOTH
Hoth Therapeutics, Inc. is a development stage biopharmaceutical company focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema. The Company is engaged in developing and commercializing the BioLexa Platform. BioLexa Platform is a proprietary, patented antimicrobial therapy. The BioLexa Platform traps all the zinc ions by adding a chelator called DTPA, which prevents Staph biofilm formation. It intends to explore the use of the BioLexa Platform for the treatment of atopic dermatitis, or eczema. It also focuses on exploring the use of the BioLexa Platform in the aesthetic dermatology field to help treat and reduce post-procedure infections, accelerate healing and improve clinical outcomes for patients undergoing procedures.
Hot Stocks

Webull offers kinds of Hoth Therapeutics Inc stock information, including NASDAQ:HOTH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HOTH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HOTH stock methods without spending real money on the virtual paper trading platform.